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Background: Corticosteroids are commonly prescribed in palliative care for alleviation of both specific and non-specific
symptoms, but relatively little is known of the perspectives of clinicians and what influences their prescribing in this
context. The aim of this study was to explore the experiences and perspectives of those involved in the prescribing of
corticosteroids in palliative care.
Methods: Semi-structured interviews were undertaken with 12 medical practitioners and six senior nurses from a
sample of six New Zealand hospices to identify their experiences and attitudes regarding the prescribing of
corticosteroids. A general inductive approach was used to thematically analyse data.
Results: Five broad themes were identified: the role of corticosteroids in palliative care; indications for corticosteroids;
influences on prescribing; use of guidelines; and perceptions of previous study data on prescribing patterns for their
hospice. Interviewees regarded these agents as having an important place in in palliative care but expressed a
degree of uncertainty about certain aspects of their use. They were concerned about issues such as prescribing for
non-specific indications, methods of stopping, and lack of monitoring and reviewing. Guidelines were used routinely
by only one of the sample hospices. Corticosteroids tended to be prescribed experientially or by habit, rather than
based on evidence-based guidelines.
Conclusions: This study has highlighted differences in the understanding of the place of corticosteroids in palliative
care by the clinicians interviewed in this study and different practices, particularly in the treatment of non-specific
symptoms and in the use of guidelines. These findings suggest a need for further research and discussion about the
role of corticosteroids in palliative care and the development of evidence-based guidelines to assist prescribers.
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Corticosteroids are a potent group of medicines which
have been used in palliative care since the late 1950s
to alleviate both specific and non-specific debilitating
symptoms [1-5]. The proportion of palliative care pa-
tients prescribed corticosteroids has been reported as
ranging from 32% to 80%, with a median of about 60%
[1-4,6-13]. In a recent New Zealand study of corticoster-
oid prescribing in palliative care, we observed that 65%
of patients received at least one course of corticosteroids
and there was a marked consistency in prescribing* Correspondence: j.shaw@auckland.ac.nz
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article, unless otherwise stated.frequency across the six sample hospices (range: 61-69%)
[14]. There were similarities between the hospices in the
choice of agents, dose ranges, and indications for use,
however, they differed considerably in the use of guide-
lines, recording of adverse effects, review and monitoring,
and the process for stopping these medicines [14].
A number of authors have suggested that prescribing
of corticosteroids is unsupported by rigorous evidence
and particular concern has been expressed about their
‘non-specific’ use [2,15-23]. Caution has to be exercised
regarding this issue as there are different perceptions
of what constitutes ‘non-specific’, with some authors
restricting the definition to anorexia-cachexia symptoms
(anorexia, fatigue, weight loss), whereas others includeentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 Semi-structured interview questions frame
Section Questions
1. Role and background of interviewee
2. Personal philosophy of corticosteroid prescribing in
palliative care
3. Knowledge and understanding of corticosteroids
4. Influences on prescribing and choice of corticosteroids
in palliative care
5. Their perceptions of the previous study data for their hospice
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[24,25]. In our previous study, the term non-specific was
used when the reasons for prescribing were not clear,
that is when there was no record of the cause of the
symptom. If, for example, pain was due to spinal cord
compression, or dyspnoea due to lymphangitis, then this
was recorded as a specific indication for corticosteroids.
Using the broader definition, we found that 40.4% of
patients in the New Zealand study received corticoste-
roids for non-specific symptoms, with ‘general well-
being’ being a frequent indication [14].
The adverse effects of corticosteroids are well-known,
as are the challenges associated with choice of agent,
dose, duration, route, monitoring and abrupt cessation
[1,3,8,12,13,20-22,26-30]. Clinicians must balance the
potential benefits and harm associated with these potent
drugs and guidelines have been developed to assist
decision-making and curb the potential for inappropriate
prescribing [8,31]. Lundstrom and Furst (2006) have ar-
gued that guidelines need to be evidence-based to ensure
the best outcomes for patients with minimum adverse
effects, as well as being easy to follow, clinically relevant,
comprehensive, and flexible [2]. In our previous study,
guidelines were available at most sites but only one of
the six hospices used them routinely [14].
Despite the considerable literature on the benefits and
drawbacks of corticosteroids in palliative care, and on
how they are used in clinical practice, relatively little is
known of what influences prescribers in their decisions
to employ these agents. For instance, is prescribing
evidence-based or largely based on experience and habit?
Are guidelines available for prescribers and do they use
them? What influence do non-medical colleagues such as
senior nurses have on prescribing decisions?
The aim of this qualitative study was to explore clini-
cians’ perceptions of the role of corticosteroids in pallia-
tive care, and the main influences on their prescribing.
This paper represents the second phase of a larger
study on corticosteroid prescribing and was designed to
complement the first phase, a retrospective analysis of
corticosteroid prescribing in a sample of New Zealand
hospices, which was reported previously in this journal
[14]. A feature of this mixed-methods approach was that
participants were shown summary data from the retro-
spective study pertaining to both their individual hospice
and the full sample of hospices, allowing them to reflect
on their actual practice in this area.
Methods
Research design
The study was approved by the New Zealand Multi-
regional Ethics committee (MEC/08/37/EXP). Semi-
structured interviews with palliative care clinicians
(both doctors and senior nurses) were undertaken toelicit their perspectives on the prescribing of corticoste-
roids in palliative care. This qualitative approach allowed
more detailed exploration of their opinions and experi-
ences than by other methods.
Setting and participants
The setting was six hospices in the North Island of New
Zealand as described in the previous study [14] and 18
experienced clinicians were recruited using a purposive
sampling method [32]. Written consent to participate
was obtained from each clinician before commencing
and the hospice directors had given previous consent for
participation of their sites. Three clinicians were re-
cruited from each hospice, comprising two medical prac-
titioners (including the Medical Director) (M1 to M12)
and one senior palliative care nurse (N1 to N6). The
rationale for including senior nurses was that while they
were not prescribers themselves, they did contribute to
team decisions on corticosteroid prescribing.
Data collection
An interview guide (Table 1) was developed based on a
review of the literature and, in part, from the findings of
the previous study of actual corticosteroid prescribing in
the same sample hospices [14]. Before the interview,
interviewees were provided with summary data from the
previous study which were specific to each hospice, but
also compared their hospice to the average of all the
sample hospices.
The interview guide was pre-tested to ensure that the
questions were clear. The interviews were conducted
during 2010 by the first author (AD) face-to-face at the
participants’ home hospice. Interviews lasted about 45–
60 minutes and were audio-recorded and transcribed.
After transcription, the written data was checked (by a
second researcher) against the digital recordings, then
re-checked by the interviewer to address inaccuracies.
Data analysis
Each transcript was entered on an NVivo 8 qualitative
data analysis programme. A general inductive approach
was used and broad themes were identified from the ini-
tial readings of the transcripts and a basic coding
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codes were reviewed by the second author (JS) and col-
leagues versed in qualitative research. The authors then
aggregated similar narratives and developed themes that
represented the beliefs, opinions and understandings of
the clinicians. With 18 interviews, there was consider-
able overlap of data, indicating data saturation. Once the
over-arching themes were finalised, they became the
content of the qualitative research.
Results
Seven of the medical practitioners were palliative care
specialists, and five were general practitioners (family
physicians) who did not have specialist palliative care
qualifications but were very experienced. The six nurses
were senior palliative care nurses. The six sample hos-
pices included both larger urban and smaller rural loca-
tions and ranged in size from five to 18 beds; the sample
hospices were considered to be representative of hos-
pices throughout New Zealand (32 in total); these are
described in more detail in the previous paper [14]. Five
broad themes emerged from the analysis: the role of cor-
ticosteroids in palliative care; indications for corticoste-
roids; influences on prescribing; use of guidelines; and
perceptions of previous study data for their hospice.
Role of corticosteroids in palliative care
There was general agreement that corticosteroids were
prescribed differently in palliative care, with a broader
range of indications than general medicine:
“I think we have a lower threshold for prescribing
steroids than general medicine.” (M11)
Most participants supported short-term prescribing of
corticosteroids and a few commented that all palliative
care patients should have a course of corticosteroids at
some stage of their palliative care:
“Steroids are not the answer. They are the stop-gap
until you figure out the answer for a lot of our
patients.” (M1)
“It’s almost said that you don’t get a good death
without somebody having had a honeymoon of
steroids at some stage.” (M12)
Several interviewees commented about familiarity/cas-
ualness in long-term usage and observed that it was easy
once they had been added to a patient’s regimen for
them to be forgotten:
“I think drugs like steroids can slip under the radar a
bit.” (M12)In contrast, others thought that they had become more
aware of their potency and were becoming more consid-
ered and less liberal in their use:
“I think there was a time we used to think it was a
bit of a wonder drug and we just threw it in there, but
we actually think a little bit more about what we are
trying to achieve nowadays and probably use it for the
right reasons.” (N2)
Indications for corticosteroids
Many suggested they tried to be clear why the cortico-
steroid was being used and that it would be for a specific
indication:
“I try to know the indication I am using when I am
prescribing steroids. Try to be clear to myself but also
to the team, what I am trying to achieve. What the
indication is.” (M6)
All interviewees were confident with prescribing corti-
costeroids for specific indications such as neurological
symptoms or bowel obstruction. In contrast, some dis-
sented when prescribing for non-specific indications was
suggested, for instance for ‘general wellbeing’. Most re-
spondents explained that within the label of ‘general
wellbeing’ there were some very specific reasons for
prescribing:
“We do use them a lot for a sense of wellbeing but
looking at appetite as well. That is the reason we
prescribe them. To try and improve appetite and with
that comes a sense of wellbeing.” (M5)
“Loss of energy, loss of appetite and wellbeing to me is
an indication that I could prescribe steroids for.” (M6)
When asked if a corticosteroid was ever prescribed as
a ‘comfort drug’, there were mixed responses. A number
of respondents were unhappy with this term and felt
that ‘comfort’ came as a result of specific symptom
management:
“They are a symptom management drug and I think
that is what we are in the business of. If that provides
comfort then that is a bonus.” (M7)
Some participants suggested the corticosteroid was
often prescribed for the ‘comfort’ of the clinician rather
than the patient.
“Perhaps we did see it as a comfort drug, not for the
patients but for us, so that we are actively doing
something.” (N2)
Denton and Shaw BMC Palliative Care 2014, 13:50 Page 4 of 7
http://www.biomedcentral.com/1472-684X/13/50When asked if a corticosteroid could be described as a
‘fix it all’ drug, most interviewees replied in the negative:
“No. I would never just prescribe them as, oh well I
can’t think of anything better let’s try … No - I don’t
see them as a ‘fix-it-all’. They are too dangerous to do
that with. They have too many side-effects.” (M2)
Most interviewees felt that adverse effects were inevit-
able and were frequently not identified until they were
very obvious, for example Cushingoid syndrome:
“It’s the long term side effects that are actually important
and they are subtle and sneak up on you.” (M1)
Influences on prescribing
When asked if prescribing in palliative care was evidence-
based, opinions varied, with the majority unsure of the
rigour of the evidence, while a few felt the evidence
was strong:
“I don’t know if it is really - we try to be evidence
based but it is not very clear cut.” (M9)
“There are quite a few solid articles now about the
use of corticosteroids for cancer patients, for
symptom management, adjuvant therapy.” (N1)
“I don’t think the evidence is out there actually.” (M2)
When discussing intuitive and anecdotal prescribing of
corticosteroids, all but one agreed that these were major
factors in prescribing:
“I suspect so. I wonder sometimes, can you always
have a scientific reason for everything?” (N6)
Only one specialist stated that their prescribing was
specifically based on clinical findings:
“No. I think that the prescribing here would first of all
be based on clinical findings ….. It is not really a gut
feeling.” (M5)
Prior experience was a major determinant of cortico-
steroid prescribing, for example, medical practitioners
who had worked internationally responded that dexa-
methasone was the corticosteroid they had used in other
countries, and they believed there was no evidence to
suggest a change in practice in New Zealand:
“Every environment I have been in they were using
dexamethasone … I stick to the devil I know rather
than trying to find out about the devil I don’t.” (M11)Some respondents said prescribing was an ‘institutional
habit’ and each unit appeared to have its unique culture:
“We work in a team and we try and get consistency of
prescribing. If you try and get medical practitioners to
prescribe the same way, that’s like herding cats.” (M11)
Guidelines
Five hospices reported use of guidelines but these varied
considerably in their use and interpretation. One had
guidelines that were used routinely, others used them
for a few specific indications only, or had guidelines but
didn’t use them. Only one hospice chose not to have
guidelines as they preferred to prescribe individually for
their patients.
“We have protocols, which are agreed upon by the
medical team, and then the team. When we initiate
steroids, we prescribe them on a tapering protocol to
zero. So that is how they get prescribed from onset to
completion.” (M6)
“Yes we do have guidelines for different situations.
Certainly we have got one for spinal cord
compression.” (M7)
“I do not do guidelines particularly well. I’m not
saying if it is a good thing or a bad thing. I don’t think
we have steroid guidelines.” (M1)
“I am not a fan of hard and fast rules – [such as]
protocols for steroids, because you are weighing up so
many things and it is not about the physical stuff –
often it is about quality as well.” (M2)
Perceptions of previous study data for their hospice
Interviewees were asked to reflect on the data on actual
prescribing for their hospice (described in Methods).
Some of their perspectives are listed in Table 2.
Some interviewees were surprised at where their hos-
pice sat within the range of patients prescribed cortico-
steroids but were agreeably surprised at its closeness, as
this suggested their prescribing was consistent with the
‘norm’. The degree of prescribing for non-specific/gen-
eral wellbeing indications was commented on with sur-
prise and/or disappointment, although some suggested
that when the reason for prescribing was too difficult to
explain to a patient, the term general wellbeing was
often used.
The small proportion of patients reviewed and moni-
tored was a disappointment to the interviewees who
agreed that these were not done well. With the input of
a number of teams (e.g. hospice, hospital, Oncology,
general practice), they suggested it was not easy for a
Table 2 Interviewees’ perceptions of their individual hospice data
Data Responses
The proportion of patients prescribed corticosteroids
across the six hospices (range: 61% to 69%)
The interviewees were mostly surprised where their relative corticosteroid usage lay:
“Interesting. I would not have put us as great steroid users… we are leading the ranks
on this study.” (M1)
“I thought probably the use in our [hospice name] was quite high and it is lower than
the other hospices so that surprises me.” (M4)
“I think that is very representative.” (M5)
“I was a little surprised it [the range] was so narrow.” (N3)
The proportion of corticosteroids prescribed for non-specific/
general wellbeing indications (range: 33% to 61%)
All were surprised at the proportion of patients being prescribed corticosteroids
for non-specific/general wellbeing indications and some went so far as to say they
found it disappointing:
“I am surprised that general well being is so high.” (M12)
“45% for wellbeing. Well that is disappointing.” (M3)
The proportion of corticosteroid adverse effects
not recorded. (range: 55% to 85%)
There was no surprise here but it was acknowledged that it was an issue some said
they found upsetting:
“The ‘not recorded’ it is always an issue.” (M1)
“I was pretty upset with the not recorded.” (M5)
The method of stopping corticosteroids
stopped abruptly - (range: 14% to 34%)
Disappointment was expressed over abrupt cessation of corticosteroids particularly
when the patient had been on them for more than three weeks. The general
feeling was surprise at the low numbers of patients who had had their corticosteroids
reduced gradually:
“I was rather taken aback about the abrupt ceasing. That surprised me because that
certainly will not be a conscious thing.” (M11)
“I am surprised that gradually is so small.” (M12)
The proportion of corticosteroids monitored
and reviewed (range: 29% to 69%)
Surprise and disappointment were expressed at the low percentage of reviewed and
monitored patients:
“I was surprised to see that only 57% of the patients were reviewed. I would have
thought that it would have been higher than that.” (M4)
“It’s really the ownership of the steroid that’s the issue. We work with oncologists
and everybody but the policing and appropriation of the steroid, that is where the
system falters.” (M11)
“It doesn’t surprise me that there is a large amount where it has not been recorded.
I don’t think that we are very good at recording.” (M2)
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seemed to be a general acceptance that adverse effects
were inevitable and therefore not generally recorded in
the patient notes; interviewees suggested that the lack of
recording was not corticosteroid-specific. They expressed
concern at the number of patients who had long-term
corticosteroids stopped abruptly and were disappointed
with the small number of regimens that were reduced
gradually. Most were aware that patients prescribed cor-
ticosteroids for more than two to three weeks may have
developed adrenal insufficiency.
Discussion
This qualitative study was set in the wider context of a
previous study in which a ‘snapshot’ of actual prescribing
was undertaken in the same six hospices where these
clinicians were based [14]. A strength of this mixed-
methods approach was that interviewees were able to
comment on the summary data from the previous studywhich showed how prescribing practice at their hospice
compared to others in the sample. To the best of our
knowledge, this is the first qualitative study of its kind,
although there have been a number of quantitative stud-
ies which have documented corticosteroid prescribing
practices [1-5,7,9-12]. The interviews with clinicians
yielded rich insights into the place of these drugs in pal-
liative care and the main influences on their prescribing.
Opinions expressed were diverse and there were few areas
in which there was full consensus, perhaps reflecting the
nature of the available evidence to guide prescribing.
Interviewees agreed that prescribing of corticosteroids
in palliative care was more frequent and more diverse
than in general medicine. None were surprised by the
relatively high proportions of patients prescribed corti-
costeroids (about two-thirds) which was in line with
reported practice internationally [1-4,6-13,33]. Indeed,
most took reassurance in this consistency as they pre-
sumed it gave credibility to their prescribing. There were
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ing which were variously described as evidence-based, ex-
periential, anecdotal or intuitive. Many interviewees cited
a lack of rigorous evidence and confusing literature and
suggested their prescribing of corticosteroids was largely
based on the established ‘culture’ at their hospice and
particularly influenced by the specialist medical staff.
As previously reported, non-specific symptoms/general
wellbeing were the main indications for prescribing in
these hospices [14]. These indications (e.g. lack of appe-
tite or fatigue) can difficult to define and, as in the litera-
ture, there was some confusion amongst participants as
to the meaning of these terms. Some interviewees asserted
that there were specific reasons for prescribing under the
banner of ‘general wellbeing’ or ‘non-specific’ indications.
A recent well-designed trial of dexamethasone has shown
significant reductions in cancer-related fatigue in patients
with advanced cancer [34]. Given the lack of clarity on
what constitutes a non-specific indication, our previous
rather negative interpretation of the finding that about
40% of prescribing was for non-specific symptoms, may
need to be viewed more positively [14]. Clinicians were
firm in their view that the use of corticosteroids as ‘fix it
all’ or ‘comfort’ drugs was inappropriate. We believe that
further debate on the definitions of ‘non-specific’, ‘general
wellbeing’ and the use of corticosteroids in these contexts
is merited.
Most hospices had guidelines for corticosteroid prescrib-
ing, but there was considerable variation in their use and
interpretation, and only one of the hospices appeared to
use them routinely. Whilst guidelines were similar to those
used internationally (e.g. at www.palliativedrugs.com) (31),
interviewees reported that dose reductions, duration, and
method of stopping differed between hospices and be-
tween prescribers, with little apparent attention paid to
guideline suggestions. It is easy to view this as a negative
finding; it would, however, be more profitable to undertake
further research into the use of guidelines – for example,
how useful are they, who uses them, and what are the
reasons they are not used more widely?
In our previous study, monitoring and review of corti-
costeroids was documented in 52% of cases and adverse
effects in 32% [14]. When shown this summary data, in-
terviewees were surprised and disappointed at these rela-
tively low levels of recording. They suggested that while
review and monitoring were frequently performed, this
may not have been recorded in the patients’ notes. Some
clinicians conceded that adverse effects were under-
recorded and often not identified until a patient was
frankly Cushingoid. Only one hospice routinely used a
corticosteroid tapering protocol. Poor documentation is
not something that is specific to corticosteroid use and
is a recurring limitation of all retrospective research.
It would be useful to conduct prospective studies ofcorticosteroid prescribing to determine the true frequency
of review and monitoring, and adverse effect recording.
When a patient has been on a corticosteroid for longer
than three weeks, the dose should be reduced gradually
to avoid an adrenal crisis as abrupt cessation can result
in terminal restlessness and anxiety, and even hasten
death [20,28-30]. In our previous study, abrupt cessation
of corticosteroids occurred in 23% of all cases and, in
approximately half of these, the course was longer than
three weeks [14]. Some clinicians were aware that corti-
costeroids had been abruptly discontinued at a relatively
high dose, especially when a patient could no longer
swallow, but did not appear particularly concerned with
this decision. Although this appears to be acceptable
practice internationally, it is both clinically and ethically
questionable as the resulting adrenal crisis may increase
terminal restlessness [20]. This issue merits further
debate, particularly as parenteral formulations of these
medicines are available and a route change is possible in
these cases [13].
This study has several limitations. It was designed to
shed light on how palliative care clinicians (medical
practitioners and senior nurses) view the place of corti-
costeroids in their hospices, and the various factors that
influence their prescribing. The clinicians were drawn
from a small sample of hospices in New Zealand; these
may not be representative of practice in other countries
and this limits the generalizability of the findings. In
addition, the palliative care community in New Zealand
is fairly small and close-knit, which may have led to a
degree of uniformity in clinicians’ perceptions and re-
sponses. Despite these limitations, some challenging
issues in the prescribing of this important group of med-
icines have been identified and should be further de-
bated in an international context. We suggest that there
is a particular need for debate on the use of corticoste-
roids for non-specific indications and further research
on the utility of evidence-based guidelines.
Conclusion
By exploring New Zealand clinicians’ perspectives of
corticosteroid prescribing in palliative care, it was found
that guidelines were used infrequently and these medi-
cines tended to be used experientially and anecdotally,
rather than based on rigorous evidence. Individual
clinicians differed in their corticosteroid prescribing
practices on a number of issues, for example dosing,
duration and method of stopping. There was some un-
certainty about their role in palliative care, particularly
for the treatment of non-specific symptoms. These find-
ings suggest that there is a need for further research,
particularly around the non-specific prescribing of cor-
ticosteroids and the use of evidence-based guidelines to
assist prescribers.
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